Skip to content
    GRDN
    Earnings call· Jun 2026(Q2 FY26)

    Guardian Pharmacy Services Q2 FY26 earnings call GRDN

    Aug 6, 2026 Source

    Executive summary

    Guardian Pharmacy Services Q2 FY26 — Strong EBITDA Growth Amid IRA Headwinds

    Guardian Pharmacy Services delivered a solid second quarter, demonstrating strong underlying business growth and effective mitigation of IRA pricing impacts on profitability. The company raised its full-year guidance for both revenue and adjusted EBITDA, driven by operational efficiencies and strategic expansions. Leadership transitions were completed to support future growth, while capital deployment remains focused on M&A and greenfield opportunities, with an eye on potential Omnicare assets.

    Highlights

    5

    • Reported revenue grew 2% in Q2 FY26, with underlying growth (absent IRA impact) in low double digits.

    • Adjusted EBITDA grew 23% in H1 FY26 compared to H1 FY25, reaching $29.7 million in Q2 FY26, up 19% YoY.

    • Full-year 2026 revenue guidance raised to $1.43 billion to $1.45 billion (from $1.4 billion to $1.42 billion).

    • Full-year 2026 adjusted EBITDA guidance raised to $129 million to $131 million (from $123 million to $127 million).

    • Cash balance increased to nearly $90 million at quarter end, up from approximately $65 million in the prior quarter.

    Concerns

    4

    • IRA pricing reductions negatively impacted reported revenue growth, which would have been low double digits without it.

    • Reported revenue is expected to decline by a low single-digit percentage in H2 FY26 due to continued IRA impact.

    • Recent acquisitions and greenfield startups continued to dilute consolidated adjusted EBITDA margin by approximately 60 basis points in Q2.

    • Higher fuel costs continued to pressure gross profit in Q2 FY26.

    Guidance & targets

    6
    CategoryTargetConfidence
    Full-year 2026 Revenue
    $1.43 billion to $1.45 billion
    high materiality
    High
    Full-year 2026 Adjusted EBITDA
    $129 million to $131 million
    high materiality
    High
    Underlying Revenue Growth (ex-IRA)
    high single digits
    medium materiality
    Medium
    Reported Revenue Growth
    decline year-over-year by a low single-digit percentage
    medium materiality
    Medium
    Adjusted EBITDA Margin
    remain relatively stable
    medium materiality
    Medium
    Adjusted EBITDA Margin
    typical seasonal increase
    medium materiality
    Medium

    Operational metrics

    20
    Reported Revenue Growth
    2%YoY
    Q2 FY26

    Reported revenue for the quarter was $351.2 million.

    Underlying Revenue Growth (ex-IRA)
    low double digitsYoY
    Q2 FY26

    Absent IRA-related pricing reductions, revenue would have been up low double digits year-over-year in the quarter.

    Adjusted EBITDA Growth
    23%YoY
    H1 FY26 vs H1 FY25

    During the first half of 2026 compared with the first half of 2025.

    Gross Profit
    $80 millionup 18% year-over-year
    Q2 FY26

    Gross profit increased to $80 million in the quarter, up 18% year-over-year with a gross margin of 22.8%.

    Gross Margin
    22.8%
    Q2 FY26

    Achieved despite continued pressure from higher fuel costs.

    SG&A
    $56.5 million
    Q2 FY26

    SG&A represented 16.9% of revenues in the quarter, in line with expectation.

    SG&A as % of Revenue
    16.9%
    Q2 FY26

    In line with expectation.

    Acquisition/Greenfield Dilution to Consolidated Margin
    60 basis pointscompared with 80 basis points in Q1
    Q2 FY26

    These locations remain below our corporate margin and reduced consolidated margin by approximately 60 basis points during the quarter.

    Effective Tax Rate
    26%
    Q2 FY26

    In line with expectations.

    Net Income
    $22.1 millioncompared to $8.8 million in the year ago quarter
    Q2 FY26

    Inclusive of the $8.5 million payer dispute settlement.

    Payer Dispute Settlement
    $8.5 million
    Q2 FY26

    Recognized as other income in the second quarter, excluded from adjusted EBITDA as not reflective of ongoing operating performance.

    Stock-Based Compensation
    $2.9 million
    Q2 FY26

    Expected to remain near this level on a quarterly basis for the balance of the year.

    Cash Balance
    nearly $90 millionup from approximately $65 million in the prior quarter
    Q2 FY26 end

    Cash conversion returned to a more normalized level following a one-time working capital reset associated with IRA implementation in Q1.

    Clinical Interventions
    over 50,000
    H1 FY26

    Pharmacy teams completed these interventions across a population of over 300,000 residents.

    Allergy Risks Identified
    approximately 4,000
    H1 FY26

    Identified as part of clinical interventions.

    Duplicate Drug Therapies Identified
    5,000 instances
    H1 FY26

    Identified as part of clinical interventions.

    M&A Ramp-up Time
    roughly 4 years
    ongoing

    Time for new locations (acquisitions and greenfields) to reach corporate average profitability.

    IRA 2027 Tranche Impact (Estimated)
    about 40%of 2026 tranche impact
    2027

    Guesstimate based on relative volume of the '27 tranche relative to the '26 tranche; revenue impact expected to be less in '27 than '26.

    Class B Common Stock Conversion
    approximately 13.5 million
    late September

    Represents the final tranche of Class B common stock converting to Class A common stock.

    Class A Common Stock Held by Employees/Management/Directors Post-Conversion
    35 million to 37 million
    post-conversion

    Includes shares they hold today; nearly all subject to a closed window trading restriction until early to mid-November.

    Industry KPIs

    4
    MetricValueDetails
    Utilization trendsover 50,000interventions
    Pharmacy scripts specialtyhigh single digits%
    Membership covered lives by lineover 210,000residents
    Adjusted EPS EBITDA leverage guidance$29.7MUSD

    Deals & partnerships

    2
    Wellness ConceptsAcquisition of a long-term care pharmacy based in the Shenandoah Valley of Virginia.

    Adds a service-oriented team with a strong reputation for quality; smaller in size but in line with desired pharmacy type.

    Lexington, KentuckyLaunch of a new greenfield pharmacy.

    Marks Guardian's first location in Kentucky; collaborative effort between Tennessee and Cincinnati pharmacies; led by David Brown.

    Risks & headwinds

    4
    IRA pricing reductionsH2 FY26

    Expected low single-digit percentage decline in H2 FY26 reported revenue

    Mitigation: Disciplined execution across the business; successful mitigation of profitability impact; PBM arrangements.

    Higher fuel costsQ2 FY26

    Pressured gross profit in Q2 FY26

    Mitigation: Implied by overall profitability management, but not explicitly stated.

    Dilution from recent acquisitions and greenfield startupsQ2 FY26

    Reduced consolidated adjusted EBITDA margin by approximately 60 basis points in Q2 FY26

    Mitigation: Continued progress in bringing these locations closer to consolidated margin.

    Uncertainty around Omnicare assetsOngoing

    Potential M&A opportunity, but deal not closed

    Mitigation: Maintaining financial flexibility ('dry powder') and standing by in case of divestiture opportunities.

    What to watch in Q3 FY26

    5

    Omnicare asset divestiture

    Next quarter
    CurrentDeal not closed, company standing by
    TargetClarity on divestiture process or opportunity

    Why it matters

    Could represent a significant M&A opportunity for Guardian, impacting capital deployment strategy.

    Also, at this point, we want to maintain dry powder until we know for certain what happens with the Omnicare assets in case there's any opportunity there.

    Q&A highlights

    6

    How long do new acquisitions/greenfields take to reach corporate average profitability, and what is the pipeline for future M&A/greenfields?

    New locations typically take about 4 years to reach corporate average profitability. The company has a very robust pipeline for both greenfields and M&A activity.

    “We've always said that it takes us roughly 4 years to bring these new locations up to the corporate average profitability, some quicker, some may be a little longer depending on what has to be done.”

    asked by Brian Tanquilut · answered by Fred Burke

    2 min read7 chapters

    Detailed Narrative

    01

    IRA Impact and Mitigation

    Guardian Pharmacy Services successfully navigated the impact of IRA pricing reductions, which otherwise would have shown low double-digit revenue growth. Despite reported revenue pressure, adjusted EBITDA grew significantly due to disciplined execution and improved profitability. Management estimates the revenue impact from the next tranche of IRA changes in 2028 to be less severe than the 2026 tranche, representing about 40% of the 2026 impact.

    02

    Leadership Transitions

    Fred Burke announced key leadership changes, with David Morris transitioning from CFO to COO and Will Mudd appointed as the new CFO. These internal promotions highlight the company's talent depth and succession planning, aiming to strengthen operational execution and financial discipline for future growth. Kendall Forbes, a co-founder, also retired, with gratitude expressed for his contributions.

    03

    Operational Excellence and Clinical Initiatives

    David Morris highlighted the company's clinical capabilities, serving over 300,000 residents and completing over 50,000 clinical interventions in the first half of 2026. The falls risk program is expanding, showing meaningful improvement in early data. These initiatives aim to reduce medication-related risks and prevent adverse health outcomes, strengthening the value proposition for facility partners and engaging payers.

    04

    M&A and Greenfield Expansion Strategy

    Guardian continues to pursue M&A and greenfield start-ups as key capital deployment strategies. Subsequent to quarter end, the company acquired Wellness Concepts in Virginia and launched a new greenfield pharmacy in Lexington, Kentucky. These expansions are consistent with their strategy of geographic growth and leveraging local market expertise, with new locations typically reaching corporate average profitability in about four years.

    05

    Regional Leadership Structure

    A new regional leadership structure has been implemented, appointing eight Senior Vice Presidents from within the company. These experienced operators will provide guidance and assistance to local pharmacies, foster best practice sharing, and strengthen communication between pharmacies and the support organization. The objective is to bring greater consistency and accountability while preserving entrepreneurial culture and local decision-making.

    06

    Class B to Class A Stock Conversion

    The final tranche of Class B common stock, approximately 13.5 million shares, is expected to convert to Class A common stock in late September. Management and directors holding a substantial majority of these shares are committed to a measured approach to liquidity to ensure an orderly process with minimal market disruption🌐, with a trading restriction until early to mid-November.

    07

    Cash Position and Capital Deployment

    The company ended the quarter with nearly $90 million in cash, up from $65 million, reflecting normalized cash conversion. While M&A and greenfield remain the primary focus for capital deployment, the company is maintaining 'dry powder' to remain flexible for potential opportunities, such as the Omnicare assets, and is exploring all options for capital allocation.

    AI-generated summary of the company’s earnings call. Not investment advice.